Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 1/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.32 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.32 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.32 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6987093 | 0.84 | ADAM17 (0.44) | ADAM17TGFBR1CCNA2CDK2CCNA1 | |
| SCHEMBL6946853 | 0.84 | ADAM17 (0.50) | ADAM17TGFBR1CCNA2CDK2CCNA1 | |
| SCHEMBL6987120 | 0.83 | ADAM17 (0.43) | ADAM17TGFBR1 | |
| SCHEMBL6984901 | 0.83 | ADAM17 (0.43) | ADAM17TGFBR1 | |
| SCHEMBL6986307 | 0.83 | ADAM17 (0.47) | ADAM17TGFBR1CCNA2CDK2CCNA1 | |
| SCHEMBL6988787 | 0.83 | ADAM17 (0.47) | ADAM17TGFBR1CCNA2CDK2CCNA1 | |
| SCHEMBL6982384 | 0.83 | ADAM17 (0.47) | ADAM17TGFBR1 | |
| SCHEMBL6986009 | 0.82 | ADAM17 (0.40) | ADAM17TGFBR1CCNA2CDK2CCNA1 | |
| SCHEMBL6983510 | 0.82 | ADAM17 (0.52) | ADAM17HPGDSMN1; SMN2 | |
| SCHEMBL6945370 | 0.82 | ADAM17 (0.49) | ADAM17TGFBR1CCNA2CDK2CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1089964-B1 | HYDRAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2003-10-29 | — | — | EP | disclosed |
| US-6239151-B1 | TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES, OSTEOARTHRITIS, RESPIRATORY DISEASES, TUMORS, CACHEXIA, CARDIOVASCULAR DISEASES, FEVER, HAEMORRHAGE AND SEPSIS, HYDRAZINE DERIVATIVES, | HOFFMANN-LA ROCHE INC. | 2001-05-29 | — | — | US | disclosed |